Zevra Therapeutics
7 Hawkeye Drive
Suite 103
North Liberty
Iowa
52317
United States
Tel: 319-665-2575
Fax: 319-665-2577
Website: http://www.kempharm.com/
Email: info@kempharm.com
240 articles about Zevra Therapeutics
-
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
10/19/2021
KemPharm, Inc. today announced that its shares of common stock have been approved for listing to The Nasdaq Global Select Market.
-
KemPharm to Present at the Benzinga Healthcare Small Cap Conference
9/27/2021
KemPharm, Inc. today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2001.
-
KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
9/23/2021
KemPharm, Inc. today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27-30, 2021.
-
KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
9/9/2021
KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
-
KemPharm Appoints Tamara A. Seymour to Board of Directors
8/18/2021
KemPharm, Inc. announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee.
-
KemPharm Reports Second Quarter 2021 Financial Results
8/12/2021
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its financial results for the second quarter ended June 30, 2021.
-
KemPharm to Report Second Quarter 2021 Results
8/5/2021
KemPharm today announced the Company will host a Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET
-
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
7/21/2021
KemPharm, Inc. today announced the U.S. commercial launch of AZSTARYS™
-
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement - June 18, 2021
6/18/2021
KemPharm, Inc. announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placement new warrants to purchase up to 1,529,379 shares of its common stock.
-
KemPharm Issues Letter to Shareholders
6/16/2021
KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders to be held on June 17, 2021.
-
KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
6/9/2021
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution.
-
KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences
6/3/2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will participate in a panel discussion on the regulatory environment during the COVID-19 pandemic at the Consero Global IP Management and IP Life Sciences Virtual Forum taking place June 7-8, 2021.
-
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
5/26/2021
SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™
-
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
5/7/2021
KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA
-
KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital
4/21/2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced receipt of a regulatory milestone payment of $10 million for the FDA approval of AZSTARYS™ in accordance with the recently amended definitive collaboration and license agreement with Commave Therapeutics,
-
KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™
4/8/2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors
-
KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
3/11/2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the fourth quarter and year ended December 31, 2020.
-
KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results
3/9/2021
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET
-
KemPharm to Present at the 33rd Annual Roth Conference
3/4/2021
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present at the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.
-
KemPharm announced this week that the U.S. Food and Drug Administration has approved its novel ADHD drug for use in patients six years and older.